LNSR Quote, Financials, Valuation and Earnings

Butterfly Network has a net margin of -111.78% compared to LENSAR's net margin of -65.81%. LENSAR's return on equity of -134.77% beat Butterfly Network's return on equity of -32.72%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 7.22%. On the other hand Butterfly Network has an analysts' consensus of $4.17 which suggests that it could grow by 75.07%. Given that Butterfly Network has higher upside potential than LENSAR, analysts believe Butterfly Network is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Butterfly Network has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Butterfly Network offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Butterfly Network pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $16.7M, which are smaller than Butterfly Network quarterly revenues of $21.2M. LENSAR's net income of -$18.7M is lower than Butterfly Network's net income of -$14M. Notably, LENSAR's price-to-earnings ratio is -- while Butterfly Network's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 3.01x versus 6.06x for Butterfly Network. Usually stocks with elevated PS ratios are considered overvalued.

Intelligent Bio Solutions has a net margin of -111.78% compared to LENSAR's net margin of -370.29%. LENSAR's return on equity of -134.77% beat Intelligent Bio Solutions's return on equity of -164.63%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 7.22%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 782.35%. Given that Intelligent Bio Solutions has higher upside potential than LENSAR, analysts believe Intelligent Bio Solutions is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $16.7M, which are larger than Intelligent Bio Solutions quarterly revenues of $607.5K. LENSAR's net income of -$18.7M is lower than Intelligent Bio Solutions's net income of -$2.2M. Notably, LENSAR's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 3.01x versus 1.56x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -111.78% compared to LENSAR's net margin of -63.81%. LENSAR's return on equity of -134.77% beat Standard BioTools's return on equity of -26.52%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 7.22%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 108.33%. Given that Standard BioTools has higher upside potential than LENSAR, analysts believe Standard BioTools is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.804, suggesting its more volatile than the S&P 500 by 80.443%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $16.7M, which are smaller than Standard BioTools quarterly revenues of $40.8M. LENSAR's net income of -$18.7M is higher than Standard BioTools's net income of -$26M. Notably, LENSAR's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 3.01x versus 2.51x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

NeuroPace has a net margin of -111.78% compared to LENSAR's net margin of -24.46%. LENSAR's return on equity of -134.77% beat NeuroPace's return on equity of -216.38%.

LENSAR has a consensus price target of $15.00, signalling upside risk potential of 7.22%. On the other hand NeuroPace has an analysts' consensus of $16.86 which suggests that it could grow by 30.17%. Given that NeuroPace has higher upside potential than LENSAR, analysts believe NeuroPace is more attractive than LENSAR.

LENSAR has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NeuroPace has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

LENSAR has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroPace offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR pays -- of its earnings as a dividend. NeuroPace pays out -- of its earnings as a dividend.

LENSAR quarterly revenues are $16.7M, which are smaller than NeuroPace quarterly revenues of $21.5M. LENSAR's net income of -$18.7M is lower than NeuroPace's net income of -$5.3M. Notably, LENSAR's price-to-earnings ratio is -- while NeuroPace's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR is 3.01x versus 4.72x for NeuroPace. Usually stocks with elevated PS ratios are considered overvalued.